The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Octreotide     10-(4-aminobutyl)-19-[(2- amino-3-phenyl...

Synonyms: Octreotida, Longastatin, Sandostatin, Sandostatine, Sandoz 201-995, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Octreotide


Psychiatry related information on Octreotide


High impact information on Octreotide


Chemical compound and disease context of Octreotide


Biological context of Octreotide

  • However, after 12 weeks of treatment, the mean glomerular filtration rate was significantly lower in the octreotide group (136 mL/min per 1.73 m2; range, 91 to 158 mL/min per 1.73 m2) than in the placebo group (157 mL/min per 1.73 m2; range, 138 to 184 mL/min per 1.73 m2) [18].
  • Comparison of the pharmacokinetics of octreotide injected at two subcutaneous sites [19].
  • 60 min after breakfast the mean sitting blood pressure was 35 +/- 10 (SEM) mm Hg higher after administration of SMS-201-995 0.4 microgram/kg than after placebo (p less than 0.001) [20].
  • A continuous octreotide infusion did not decrease portal pressure [21].
  • The 4-nitrobenzo-2-oxa-1,3-diazol-labeled peptide was active in displacing the corresponding hormone 125I-Tyr3-SMS 201-995 (Sandostatin; Sandoz Pharmaceuticals, Basel, Switzerland) from its high-affinity binding site in rat cortex membranes with an IC50 = 4.6 x 10(-10) mol/L [22].

Anatomical context of Octreotide


Associations of Octreotide with other chemical compounds


Gene context of Octreotide


Analytical, diagnostic and therapeutic context of Octreotide


  1. Successful pregnancy in a previously infertile woman treated with SMS-201-995 for acromegaly. Landolt, A.M., Schmid, J., Wimpfheimer, C., Karlsson, E.R., Boerlin, V. N. Engl. J. Med. (1989) [Pubmed]
  2. Visual improvement with SMS 201-995 in a patient with a thyrotropin-secreting pituitary adenoma. Guillausseau, P.J., Chanson, P., Timsit, J., Warnet, A., Lajeunie, E., Duet, M., Lubetski, J. N. Engl. J. Med. (1987) [Pubmed]
  3. Sclerotherapy with or without octreotide for acute variceal bleeding. Besson, I., Ingrand, P., Person, B., Boutroux, D., Heresbach, D., Bernard, P., Hochain, P., Larricq, J., Gourlaouen, A., Ribard, D. N. Engl. J. Med. (1995) [Pubmed]
  4. Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. Reznik, Y., Allali-Zerah, V., Chayvialle, J.A., Leroyer, R., Leymarie, P., Travert, G., Lebrethon, M.C., Budi, I., Balliere, A.M., Mahoudeau, J. N. Engl. J. Med. (1992) [Pubmed]
  5. Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995. Boden, G., Ryan, I.G., Eisenschmid, B.L., Shelmet, J.J., Owen, O.E. N. Engl. J. Med. (1986) [Pubmed]
  6. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. Soudah, H.C., Hasler, W.L., Owyang, C. N. Engl. J. Med. (1991) [Pubmed]
  7. Octreotide as primary therapy for acromegaly. Newman, C.B., Melmed, S., George, A., Torigian, D., Duhaney, M., Snyder, P., Young, W., Klibanski, A., Molitch, M.E., Gagel, R., Sheeler, L., Cook, D., Malarkey, W., Jackson, I., Vance, M.L., Barkan, A., Frohman, L., Kleinberg, D.L. J. Clin. Endocrinol. Metab. (1998) [Pubmed]
  8. Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Prader-Willi syndrome. Haqq, A.M., Stadler, D.D., Rosenfeld, R.G., Pratt, K.L., Weigle, D.S., Frayo, R.S., LaFranchi, S.H., Cummings, D.E., Purnell, J.Q. J. Clin. Endocrinol. Metab. (2003) [Pubmed]
  9. The somatostatin analogue SMS 201-995 promotes paradoxical sleep in aged rats. Danguir, J. Neurobiol. Aging (1989) [Pubmed]
  10. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. McKeage, K., Cheer, S., Wagstaff, A.J. Drugs (2003) [Pubmed]
  11. Octreotide therapy for tumor-induced osteomalacia. Seufert, J., Ebert, K., Müller, J., Eulert, J., Hendrich, C., Werner, E., Schuüze, N., Schulz, G., Kenn, W., Richtmann, H., Palitzsch, K.D., Jakob, F. N. Engl. J. Med. (2001) [Pubmed]
  12. Treatment of cystoid macular edema with octreotide. Kuijpers, R.W., Baarsma, S., van Hagen, P.M. N. Engl. J. Med. (1998) [Pubmed]
  13. Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. D'Amico, G., Pietrosi, G., Tarantino, I., Pagliaro, L. Gastroenterology (2003) [Pubmed]
  14. Treatment of intestinal cryptosporidiosis with zidovudine and SMS 201-995, a somatostatin analog. Nousbaum, J.B., Robaszkiewicz, M., Cauvin, J.M., Garre, M., Gouerou, H. Gastroenterology (1991) [Pubmed]
  15. Gastric endocrine cell behavior in Zollinger-Ellison patients upon long-term potent antisecretory treatment. Lehy, T., Mignon, M., Cadiot, G., Elouaer-Blanc, L., Ruszniewski, P., Lewin, M.J., Bonfils, S. Gastroenterology (1989) [Pubmed]
  16. Terlipressin plus transdermal nitroglycerin vs. octreotide in the control of acute bleeding from esophageal varices: a multicenter randomized trial. Silvain, C., Carpentier, S., Sautereau, D., Czernichow, B., Métreau, J.M., Fort, E., Ingrand, P., Boyer, J., Pillegand, B., Doffël, M. Hepatology (1993) [Pubmed]
  17. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Wong, F., Pantea, L., Sniderman, K. Hepatology (2004) [Pubmed]
  18. Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetes. Serri, O., Beauregard, H., Brazeau, P., Abribat, T., Lambert, J., Harris, A., Vachon, L. JAMA (1991) [Pubmed]
  19. Comparison of the pharmacokinetics of octreotide injected at two subcutaneous sites. Patel, S.R., Kvols, L.K., Peterson, D.A., Gilbertson, D.T., Moertel, C.G., O'Dorisio, T.M. J. Natl. Cancer Inst. (1989) [Pubmed]
  20. Treatment of autonomic neuropathy with a somatostatin analogue SMS-201-995. Hoeldtke, R.D., O'Dorisio, T.M., Boden, G. Lancet (1986) [Pubmed]
  21. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Escorsell , A., Bandi, J.C., Andreu, V., Moitinho, E., García-Pagán, J.C., Bosch, J., Rodés, J. Gastroenterology (2001) [Pubmed]
  22. Intestinal absorption of the octapeptide SMS 201-995 visualized by fluorescence derivatization. Fricker, G., Bruns, C., Munzer, J., Briner, U., Albert, R., Kissel, T., Vonderscher, J. Gastroenterology (1991) [Pubmed]
  23. Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy. Lamberts, S.W., Hofland, L.J., de Herder, W.W., Kwekkeboom, D.J., Reubi, J.C., Krenning, E.P. Frontiers in neuroendocrinology. (1993) [Pubmed]
  24. Octreotide promotes gallbladder absorption in prairie dogs: a potential cause of gallstones. Moser, A.J., Abedin, M.Z., Giurgiu, D.I., Roslyn, J.J. Gastroenterology (1995) [Pubmed]
  25. Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration. Londong, W., Angerer, M., Kutz, K., Landgraf, R., Londong, V. Gastroenterology (1989) [Pubmed]
  26. Octreotide-induced pancreatitis: an effect of increased contractility of Oddi sphincter. Bodemar, G., Hjortswang, H. Lancet (1996) [Pubmed]
  27. Octreotide suppression test predicts beneficial outcome from antrectomy in a patient with gastric carcinoid tumor. Higham, A.D., Dimaline, R., Varro, A., Attwood, S., Armstrong, G., Dockray, G.J., Thompson, D.G. Gastroenterology (1998) [Pubmed]
  28. Deficiency of phosphofructo-1-kinase/muscle subtype in humans impairs insulin secretion and causes insulin resistance. Ristow, M., Vorgerd, M., Möhlig, M., Schatz, H., Pfeiffer, A. J. Clin. Invest. (1997) [Pubmed]
  29. Somatostatin analogues suppress the inflammatory reaction in vivo. Karalis, K., Mastorakos, G., Chrousos, G.P., Tolis, G. J. Clin. Invest. (1994) [Pubmed]
  30. Therapy for persistent hyperinsulinemic hypoglycemia of infancy. Understanding the responsiveness of beta cells to diazoxide and somatostatin. Kane, C., Lindley, K.J., Johnson, P.R., James, R.F., Milla, P.J., Aynsley-Green, A., Dunne, M.J. J. Clin. Invest. (1997) [Pubmed]
  31. Effects of long-term propranolol and octreotide on postprandial hemodynamics in cirrhosis: a randomized, controlled trial. Vorobioff, J.D., Gamen, M., Kravetz, D., Picabea, E., Villavicencio, R., Bordato, J., Ruf, A., Bessone, F., Romero, G., Palazzi, J., Nicora, A., Passamonti, M., Tanno, H. Gastroenterology (2002) [Pubmed]
  32. Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome. Prelević, G.M., Wurzburger, M.I., Balint-Perić, L., Nesić, J.S. Lancet (1990) [Pubmed]
  33. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. Kubota, A., Yamada, Y., Kagimoto, S., Shimatsu, A., Imamura, M., Tsuda, K., Imura, H., Seino, S., Seino, Y. J. Clin. Invest. (1994) [Pubmed]
  34. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Virgolini, I., Yang, Q., Li, S., Angelberger, P., Neuhold, N., Niederle, B., Scheithauer, W., Valent, P. Cancer Res. (1994) [Pubmed]
  35. Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. Comi, R.J., Gesundheit, N., Murray, L., Gorden, P., Weintraub, B.D. N. Engl. J. Med. (1987) [Pubmed]
  36. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. Lamberts, S.W., Uitterlinden, P., Verschoor, L., van Dongen, K.J., del Pozo, E. N. Engl. J. Med. (1985) [Pubmed]
WikiGenes - Universities